These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 17979517)

  • 1. Limitations of pharmacogenomic predictor discovery in Phase II clinical trials.
    Pusztai L
    Pharmacogenomics; 2007 Oct; 8(10):1443-8. PubMed ID: 17979517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenomic predictor discovery in phase II clinical trials for breast cancer.
    Pusztai L; Anderson K; Hess KR
    Clin Cancer Res; 2007 Oct; 13(20):6080-6. PubMed ID: 17947471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mobilizing pharmacogenomic analyses during clinical trials in drug development.
    Bienfait KL; Shaw PM; Murthy G; Warner AW
    Pharmacogenomics; 2013 Jul; 14(10):1227-35. PubMed ID: 23859576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A flexible multi-stage design for phase II oncology trials.
    Tan MT; Xiong X
    Pharm Stat; 2011; 10(4):369-73. PubMed ID: 22328328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenomics in early-phase oncology clinical trials: is there a sweet spot in phase II?
    O'Donnell PH; Stadler WM
    Clin Cancer Res; 2012 May; 18(10):2809-16. PubMed ID: 22427349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II clinical trial design: methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology Group.
    Gray R; Manola J; Saxman S; Wright J; Dutcher J; Atkins M; Carducci M; See W; Sweeney C; Liu G; Stein M; Dreicer R; Wilding G; DiPaola RS
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):1966-9. PubMed ID: 16609005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel designs and end points for phase II clinical trials.
    Adjei AA; Christian M; Ivy P
    Clin Cancer Res; 2009 Mar; 15(6):1866-72. PubMed ID: 19276272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bayesian design of single-arm phase II clinical trials with continuous monitoring.
    Johnson VE; Cook JD
    Clin Trials; 2009 Jun; 6(3):217-26. PubMed ID: 19528131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statistical designs for early phases of cancer clinical trials.
    Guan S
    J Biopharm Stat; 2012; 22(6):1109-26. PubMed ID: 23075011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal designs for two-arm, phase II clinical trial design with multiple constraints.
    Mayo MS; Mahnken JD; Soong SJ
    J Biopharm Stat; 2010 Jan; 20(1):106-24. PubMed ID: 20077252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design of phase II ALS clinical trials.
    Schoenfeld DA; Cudkowicz M
    Amyotroph Lateral Scler; 2008; 9(1):16-23. PubMed ID: 18273715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal and minimax three-stage designs for phase II oncology clinical trials.
    Chen K; Shan M
    Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimising the design of phase II oncology trials: the importance of randomisation.
    Ratain MJ; Sargent DJ
    Eur J Cancer; 2009 Jan; 45(2):275-80. PubMed ID: 19059773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II clinical trials in oncology: are we hitting the target?
    Ang MK; Tan SB; Lim WT
    Expert Rev Anticancer Ther; 2010 Mar; 10(3):427-38. PubMed ID: 20214523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.
    Karrison TG; Maitland ML; Stadler WM; Ratain MJ
    J Natl Cancer Inst; 2007 Oct; 99(19):1455-61. PubMed ID: 17895472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current pharmacogenomic approaches to clinical drug development.
    Murphy MP
    Pharmacogenomics; 2000 May; 1(2):115-23. PubMed ID: 11256585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving the design of phase II trials of cytostatic anticancer agents.
    Stone A; Wheeler C; Barge A
    Contemp Clin Trials; 2007 Feb; 28(2):138-45. PubMed ID: 16843736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Designing a series of decision-theoretic phase II trials in a small population.
    Hee SW; Stallard N
    Stat Med; 2012 Dec; 31(30):4337-51. PubMed ID: 22927289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interpreting the clinical utility of a pharmacogenomic marker based on observational association studies.
    Sorich MJ; Coory M
    Pharmacogenomics J; 2014 Feb; 14(1):1-5. PubMed ID: 24018622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal cost-effective designs of Phase II proof of concept trials and associated go-no go decisions.
    Chen C; Beckman RA
    J Biopharm Stat; 2009; 19(3):424-36. PubMed ID: 19384686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.